Infectious Disease Risk Associated with Contaminated Propofol Anesthesia, 1989–2014

Andrés Zorrilla-Vaca, Jimmy J. Arevalo, Kevin Escandón-Vargas, Daniel Soltanifar, Marek A. Mirski

Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; (4) view/print certificate.

Release date: May 11, 2016; Expiration date: May 11, 2017

Learning Objectives
Upon completion of this activity, participants will be able to:

• Assess the epidemiology of propofol-related infection.
• Identify the procedure associated with the highest number of propofol-related infections.
• Assess different sources of propofol-related infection.
• Evaluate other contributing factors in propofol-related infections.

CME Editor
Jean Michaels Jones, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Jean Michaels Jones has disclosed no relevant financial relationships.

CME Author
Charles P. Vega, MD, Clinical Professor of Family Medicine, University of California, Irvine. Disclosure: Charles P. Vega, MD, has disclosed the following financial relationships: served as an advisor or consultant for Allergan, Inc.; McNeil Consumer Healthcare; served as a speaker or a member of a speakers bureau for Shire Pharmaceuticals.

Authors
Disclosurea: Andrés Zorrilla-Vaca; Jimmy J. Arevalo, MD, MSc; Kevin Escandón-Vargas, MD; Daniel Soltanifar, MBBS, FRCA; and Marek A. Mirski, MD, PhD, have disclosed no relevant financial relationships.

Author affiliations: Universidad del Valle School of Medicine, Cali, Colombia (A. Zorrilla-Vaca, K. Escandón-Vargas); Fundación Universitaria de Ciencias de la Salud, Bogota, Colombia (J.J. Arevalo); Royal Free Hospital, London, United Kingdom (D. Soltanifar), Johns Hopkins University School of Medicine, Baltimore, Maryland, USA (M.A. Mirski)

DOI: http://dx.doi.org/10.3201/eid2206.150376

Administration of propofol, the most frequently used intravenous anesthetic worldwide, has been associated with several iatrogenic infections despite its relative safety. Little is known regarding the global epidemiology of propofol-related outbreaks and the effectiveness of existing preventive strategies. In this overview of the evidence of propofol as a source of iatrogenic infection.
infection and appraisal of preventive strategies, we identified 58 studies through a literature search in PubMed, Embase, and Lilacs for propofol-related infections during 1989–2014. Twenty propofol-related outbreaks have been reported, affecting 144 patients and resulting in 10 deaths. Related factors included reuse of syringes for multiple patients and prolonged exposure to the environment when vials were left open. The addition of antimicrobial drugs to the emulsion has been instituted in some countries, but outbreaks have still occurred. There remains a lack of comprehensive information on the effectiveness of measures to prevent future outbreaks.

Globally, propofol is the most frequently used intravenous (IV) anesthetic for the induction and maintenance of general anesthesia (1). The chemical in propofol, 2,6-diisopropylphenol, is insoluble in aqueous solutions, so the solution is formulated as a nonpyrogenic emulsion containing soybean oil, purified egg phosphatide, and glycerol. This anesthetic has several favorable characteristics as a hypnotic agent, including rapid onset and elimination times, predictability and ease of titration, and a strong overall safety profile (1). Despite these benefits, propofol has been associated with the occurrence of healthcare-related infections (2–4). The potential to cause infections has been attributed to the lipophilic nature of propofol formulations, a medium that strongly supports extrinsic bacterial growth at room temperature (5).

In 1989, the US Food and Drug Administration (FDA) approved propofol as an induction agent for general anesthesia. Since then, numerous reports of propofol-related infections have generated strong concern among public health officials (6), leading to the institution of strict aseptic handling protocols and, in some countries, the additional requirement of instilling antimicrobial additives to propofol formulations. In many countries, however, no such standards have been adopted, largely because of the additional costs involved and the argument that insufficient evidence exists for the effectiveness of such antimicrobial additives. In the United States, the American Society of Anesthesiologists and the Centers for Disease Control and Prevention have jointly recommended strict adherence to aseptic handling protocols of propofol (7).

There continues to be a lack of awareness of the occurrence of infections related to propofol use among healthcare providers (6). To our knowledge, no previous review has evaluated the characteristics of propofol-related outbreaks and the evidence supporting the use of existing preventive strategies. The aim of this article is to present an overview of the evidence of propofol as a source of healthcare-related infections.

Selection Criteria for Studies
We reviewed studies that reported on the occurrence of propofol-related infections in human subjects: single case reports, case series, retrospective chart reviews, cross-sectional studies, prospective follow-up studies, and registries published in the form of short communications or original contributions. We also reviewed laboratory studies reporting on propofol as a microbiological reservoir and studies evaluating the effectiveness of bacterial growth retardants in propofol formulations. Studies reporting on propofol-related infections in animals were excluded, as were reports found in newspaper articles and government Internet sites. The latter sources, because they are not peer-reviewed articles, provide insufficient evidence for the association between propofol and infectious events.

Search Methods for Identification of Studies
We identified appropriate articles by searching PubMed, Embase, and Lilacs for reports published during January 1, 1989–September 30, 2014. The search was limited to articles published in or after 1989, which is the year propofol was introduced to clinical practice. The electronic search strategy for PubMed was “(propofol OR Diprivan) AND (infection OR outbreak OR contamination).” The search strategy was translated in accordance to the other database Boolean operators and was not limited by language. For this study, outbreak was defined as ≥2 cases.

Study Selection
The titles and abstracts retrieved during the literature search were screened by 2 co-authors (A.Z.V., K.E.V.) independently for inclusion criteria. The full text of the selected studies was retrieved and related reference lists screened to identify additional publications. Disagreements on the selection of studies were solved by a third co-author (D.S.).

Data Extraction and Management
We stratified articles into 4 categories. 1) Features of propofol-related outbreaks worldwide (e.g., year, geographic localization, type of procedure, route of propofol contamination, type of microorganism isolated, number of cases, and number of deaths) were compiled for each outbreak during 1989–2014. Outbreak reports published more than once were occasionally encountered; only the most representative study was included to prevent data duplication. In addition, we took a conservative approach in extracting data from single cases if strong associations between propofol exposure and the infectious event were reported. 2) Laboratory-based evidence of propofol as a microbiological reservoir was retrieved regarding the frequency of contaminated propofol syringes, vials, or infusion lines used in operating rooms (ORs) or intensive care units (ICUs). 3) Epidemiologic evidence concerning
Infectious Disease Risk and Contaminated Propofol was confirmed by case-control, cohort, and clinical trial studies (online Technical Appendix, http://wwwnc.cdc.gov/EID/article/22/6/15-0376-Techapp1.pdf). 4) Studies on propofol formulations were used for evaluation of the data suggestive of a reduction in microbial growth associated with specific propofol formulations.

We screened 465 abstracts and chose 53 to examine: 25 outbreak reports, 3 reports of single cases, 7 laboratory-based studies on propofol, 10 analytical studies that supported the healthcare effect of contaminated propofol in terms of the risk for infection, and 8 studies of the alternative propofol formulations (Figure 1). We retrieved an additional 5 articles by using references cited in 3 of the initial 53 articles to expand on specific points.

Worldwide Occurrence of Outbreaks Associated with Propofol-Based Anesthesia
The risk for postoperative infection depends on a variety of factors, including wound class (i.e., clean, clean-contaminated, contaminated, or dirty), the condition of the patient, type and length of surgery, use of antimicrobial drugs, and perioperative events. During the past 2 decades, several episodes of sepsis worldwide have been reported to be associated with propofol administered by syringe injection or used as a continuous infusion (2–4,6,8–15) (Table 1). These cases were reported in industrialized countries; no outbreaks have been documented in developing or low-income countries, such as those in Latin America, Africa, or Asia (Figure 2), likely as a consequence of deficiencies of surveillance programs and poor data acquisition regarding the frequency of contaminated propofol. Propofol-associated infections likely occur in developing countries with relatively higher frequency than in industrialized countries, related to the common problem of economic restraints and reduced use of universal precautions within the healthcare systems, leading to reuse of syringes and use of vials for multiple patients.

Since this anesthetic was introduced, 20 propofol-related infectious disease outbreaks have been reported worldwide, affecting 144 patients and resulting in 10 deaths; these outbreaks have lasted between 8 hours and 65 days (Table 1). However, many outbreaks related to propofol are likely undocumented and such reports do not reflect ongoing sporadic infections that are likely to be linked to propofol use.

Figure 1. Flowchart of the selection of studies of infectious disease risk associated with contaminated propofol anesthesia, 1989–2014
Outbreaks have been associated with widely diverse types of procedures in both intensive care units (ICUs) and operating rooms (ORs) (Table 1). Although no specific clinical procedure has been causally related to propofol-related infectious outbreaks, endoscopic procedures have been the most frequently associated with propofol-related infections during the past 20 years.

Contrary to some healthcare perceptions, none of the reported outbreaks to date have been correlated with intrinsic batch-contamination of propofol. Nevertheless, some peer-reviewed reports of manufacturing deficiencies exist, as well as ≥2 outbreaks probably linked to intrinsic contamination; however, the latter were published on government Internet sites and therefore are not included in this review. A US

Table 1. Summary data of iatrogenic disease outbreaks associated with contaminated propofol reported worldwide, 1989–2014*

| Location† | No. outbreaks | Duration, d‡ | Year§ | Type of infection | Type of surgery | Microorganism¶ | No. cases | No. (%) deaths | Ref. |
|-----------|---------------|--------------|--------|------------------|----------------|----------------|-----------|----------------|------|
| California, USA | 1 | 8 | 1990 | SSI | ND | Staphylococcus aureus | 5 | ND | (6) |
| Illinois, USA | 1 | 5 | 1990 | BSI, endophthalmitis | Endarterectomy, arthroscopy, dilatation and curettage | Candida albicans | 4 | 0 | (6) |
| Maine, USA | 1 | 14 | 1990 | BSI | ND | Moraxella osloensis | 2 | 0 | (6) |
| Michigan, USA | 1 | 65 | 1990 | BSI, SSI, endophthalmitis | ND | S. aureus | 16 | 2 (12.5) | (2) |
| Houston, Texas, USA | 1 | 11 | 1990 | BSI | General, urology, gynecology | Enterobacter agglomerans | 4 | 0 | (2) |
| United States | 1 | 16 | 1992 | BSI, SSI | Orthopedics | Serratia marcescens | 6 | 0 | (2) |
| United States | 1 | 7 | 1992 | ND | Gynecology | ND | 4 | 0 | (2) |
| Paris, France | 1 | 0.33 | 1994 | BSI | ND | Klebsiella pneumoniae | 4 | 0 | (10) |
| Atlanta, Georgia, USA | 1 | 1 | 1997 | BSI | Electroconvulsive therapy | S. aureus | 5 | 1 (20) | (8) |
| Reggio Emilia, Italy | 1 | 1 | 2001 | Hepatitis C | Gynecology | HCV | 5 | 0 | (11) |
| Toronto, Ontario, Canada | 1 | ND | 2001 | BSI, SSI | Orthopedics, gastrointestinal, vascular, neurosurgery, pulmonary | S. marcescens | 7 | 2 (28.6) | (4) |
| Berlin, Germany | 1 | ND | 2002 | BSI | ND | E. cloacae | 4 | 2 (50) | (3) |
| Melbourne, Victoria, Australia | 2 | 2 | 2003 | Hepatitis C | Arthroscopy | HCV | 6 | ND | (9) |
| Las Vegas, Nevada, USA | 1 | 2 | 2008 | Hepatitis C | Endoscopy | HCV | 9# | 1 (11.1) | (13) |
| Alicante, Spain | 1 | ND | 2010 | Systemic candidiasis, endophthalmitis | Endoscopy | C. albicans | 27 | 0 | (14) |
| New York, USA | 1 | 2 | 2010 | Hepatitis C and B | Endoscopy | HCV, HBV | 12 | ND | (12) |
| Rotterdam, the Netherlands | 1 | 2 | 2010 | BSI, SIRS | Orthopedics, gynecology | K. pneumoniae, S. marcescens | 7 | 2 (28.6) | (15) |
| Hsinchu, Taiwan | 1 | 1 | 2013 | Endotoxemia | Endoscopy, colonoscopy | ND | 4 | 0 | (16) |
| Total | 20 | | | | | | 144 | 10 (9.3)** |

*Outbreak, ≥2 cases; ND, not described in publication; BSI, bloodstream infection; SSI, surgical site infection; HCV, hepatitis C virus; HBV, hepatitis B virus; ref., reference; SIRS, systemic inflammatory response syndrome.
†Location where the outbreak emerged.
‡Duration of the outbreak.
§Year of publication.
¶Causative microorganism implicated in outbreak.
#Results of HCV tests of 60,000 persons (who underwent procedures requiring anesthesia at the same clinic from March 1, 2004 through January 11, 2008) are pending. The health department identified an additional 106 infections that could have been linked to the multi-dose vials of propofol. (http://www.cdc.gov/hepatitis/Outbreaks/HealthcareHepOutbreakTable.htm).
**Death rate was estimated taking into account only the published outbreaks with mortality data reported (n = 108).
government report traced 41 cases of infection in 2009 to 1 contaminated batch (http://www.fda.gov/Safety/Recalls/ArchiveRecalls/2009/ucm172474.htm); 9 other possible cases were traced in Australia in 2014 (https://www.tga.gov.au/alert/propropofol-provive-and-sandoz-propofol-1-emulsion-injection-all-sizes-and-all-batches-update-3).

Distribution of propofol-related outbreaks has been widespread geographically (Figure 2) and temporally (Figure 3). The United States has reported 11 outbreaks, the highest number of outbreaks during the assessed period, averaging 1 every 2 years and accounting for 55% of all reported outbreaks worldwide. According to the list of healthcare-associated hepatitis B and C virus (HBV and HCV, respectively) outbreaks reported by the US Centers for Disease Control and Prevention during 2008–2014, the coincident recent exposure to propofol was considered a factor leading to the screening of >60,000 patients (http://www.cdc.gov/hepatitis/Outbreaks/PDFs/HealthcareInvestigationTable.pdf).

In a 2003 study of the literature on hospital-acquired infections worldwide, Vonberg and Gastmeier calculated a mortality rate of 13.8% related to administration of propofol (17). The data we collected indicate an estimated mortality rate in propofol–associated infections of ≈9.3% (range 0%–50%) (Table 1). This value only summarizes the current published literature describing propofol–related outbreaks, and thus it may not represent the true magnitude of the problem (2). According to an inspection of data held by AstraZeneca, 345 cases of postoperative infections or febrile syndrome occurred after propofol use in the United States during November 1989–November 2004; unfortunately, data for these cases were archived and not published (2,18).

Figure 2. Geographic distribution of propofol-related infectious disease outbreaks worldwide, 1989–2014. Values indicate number of outbreaks for each country.

Figure 3. Timing of propofol-related infectious disease outbreaks worldwide during 1989–2014. An outbreak was defined as ≥2 cases. Dashed line indicates cumulative no. case-patients (secondary y-axis).
Mechanisms of Contamination of Propofol Formulations

Microbiological contamination of propofol lipid emulsions may occur from the environment either during manufacture (intrinsic) or after vial opening (extrinsic), the latter of which is the most frequent. The horizontal transmission of pathogens in anesthesia begins with the breach of handling precautions by anesthesia providers of devices or drugs. Frequently neglected precautions during the induction and maintenance of anesthesia include hand hygiene and protection against incidental propofol contact with the environment (19–21). In addition, surreptitious use of IV anesthetics by drug-addicted healthcare workers could raise the risk for extrinsic contamination (22). Other factors that may potentially affect the sterility of propofol in clinical use include preparation of multiple syringes for use throughout the day; re-use of vials, syringes, or infusion-pump lines on >1 patient; use of opened ampules longer than recommended by the manufacturer; and failure to wear sterile gloves during handling of propofol and to dispose of them after each contact.

The most common reservoirs associated with extrinsic contamination of propofol are syringes or micro-droppers, vials, and IV stopcock dead space. Syringes or micro-droppers have been implicated in most outbreaks (23–27). Propofol vials have been demonstrated to be a reservoir for microbes when contents are exposed to the environment (28). Delays in administration after propofol vials have been opened are a recognized risk factor; the degree of contamination of an opened vial may increase by 20%–26% after 12 hours (29). Propofol is available in vials of various volumes; a typical 20-mL vial contains 200 mg, and 50- and 100-mg vials are available. It is believed that administering a dose >200 mg to an adult in an OR will increase the probability of using an additional vial as a multi-dose vial for ≥1 patients. IV stopcock dead space has been shown to provide a potential route of entry for pathogenic, multidrug-resistant bacteria in infusion lines (20,27).

A number of microorganisms are associated with propofol in clinical- and laboratory-based studies at varying frequencies (Table 2). We report the specific pathogens that have been associated in several outbreaks (2–4,6,8–10,12–15,30,31), as well as all of the transmissible microorganisms that have been observed in contaminated propofol in

### Table 2. Microorganisms identified in propofol anesthesia-relatediatrogenic infection outbreaks, single cases, or laboratory-based studies of syringes, vials, or infusion lines

| Category and microorganism | Type of infection | % Infections† | References |
|---------------------------|------------------|--------------|------------|
| **Gram-positive bacteria** |                  |              |            |
| *Staphylococcus aureus* | BSI, SSI | 27.08 | (2,6,8,30) |
| *S. epidermidis*†       |           | 27.08 | (23,27,30,31) |
| MRSE§                    | SSI       |     | (31)       |
| *Streptococcus salivarius*† |       |     | (22)       |
| Enterococcus faecalis†   |           |     | (32)       |
| *Micrococcus sp.*†       |           |     | (23,25,27) |
| Corynebacterium sp.†     |           |     | (23)       |
| Bacillus sp.†            |           |     | (23,25)    |
| Diphtheroids sp.†        |           |     | (25)       |
| Kocuria sp.†             |           |     | (27)       |
| **Gram-negative bacteria** |                  |              |            |
| *Serratia marcescens* | BSI, SSI | 20.14 | (2,4,15,30) |
| Enterobacter cloacae      | BSI       | 2.78 | (31)       |
| *E. agglomerans*         | BSI       | 2.78 | (2)        |
| *Pseudomonas cepacia*§   | BSI       | 9.72 | (34)       |
| *P. aeruginosa*§         | SSI       | 2.78 | (#)        |
| Escherichia coli‡         | BSI       | 3.47 | (10,15)    |
| *Klebsiella pneumoniae*  | BSI       | 1.39 | (6)        |
| Moraxella osloensis       | BSI, SSI  |     | (27)       |
| Acinetobacter sp.†       |           |     |            |
| **Fungus**               |                  |              |            |
| *Candida albicans*       | BSI, SSI   | 21.53 | (2,6,14,30) |
| **Viruses**              |                  |              |            |
| *HCV*                    | Hepatitis C   | 22.53 | (9,11–13)  |
| *HBV*                    | Hepatitis B   | 4.17  | (12)       |

*Outbreak, >2 cases; BSI, bloodstream infection; SSI, surgical site infection; MRSE, methicillin-resistant *Staphylococcus epidermidis*; HCV, hepatitis C virus; HBV, hepatitis B virus; dashes indicate no infections identified.
†Percentage of infection estimated among the total of victims involved only in outbreaks in which a pathogen was identified (n = 131). In total, 9.03% of the patients reported in the outbreaks had no microorganisms identified, in part because the cultures were obtained after administration of antimicrobial drugs.
‡Microorganisms that have been identified by culture of residual propofol after clinical use but so far have not been involved in propofol-related outbreaks or infection associated with propofol.
§MRSE, *P. cepacia, P. aeruginosa,* and *E. coli* have been identified in case reports of infection and septic shock, but so far have not been involved in propofol-related outbreaks.
#P. aeruginosa and HCV have been implicated in outbreaks in Catalonia and Galicia, Spain. However, these reports appeared in newspapers and because of that were not included in this synopsis article (http://elpais.com/diario/2011/03/05/sociedad/1299279606_850215.html and http://elpais.com/diario/2011/03/09/sociedad/1299625207_850215.html).
syringes, vials, and infusion lines (23,25,27,30,32). We also describe 3 reported cases of septic shock related to propofol (33,34).

Propofol is an excellent medium not only for bacterial growth but also for fungal infections, which have been associated with propofol use particularly when poor hygienic standards are observed during the administration. Viral infections with HCV and HBV have also been demonstrated, possibly explained by the viral stability offered by propofol emulsions (9,11,13). Overall, ≈23% of the published infection outbreaks associated with propofol were caused by HCV (18.1%) and HBV (4.2%); 21.5% by Candida albicans; and 47.2% by bacteria (gram-positive 27.1%, gram-negative 20.1%). In the remaining reports, no microorganisms were identified, possibly as a consequence of concurrent antimicrobial drug therapy. The most frequent pathogens associated with propofol-related outbreaks, in order of frequency, were Staphylococcus aureus (39/144), Candida albicans (31/144), and HCV (26/144).

Laboratory-based (Table 3) and epidemiologic (online Technical Appendix Table 1) microbiological studies have demonstrated that the production of bacterial endotoxins is greatly enhanced by propofol solutions. Case reports of endotoxia associated with the use of contaminated propofol have also been published (5,34,35).

**Frequency of Contaminated Propofol Used in ICUs and ORs**

Microbiological observations of opened propofol vials were reported in the first studies that identified bacterial growth in propofol, and observational studies on propofol formulations have determined the proportion of extrinsic contamination (Table 3). In 1994, Farrington et al. established an incidence rate of 6% (3/50) of contaminated propofol syringes in an ICU (31). Webb et al. retrospectively observed similar results in a different ICU setting with an incidence of 5.9% (18/302) (23). Soong observed a lower propofol contamination incidence (3.0%) in ORs and also noted an association between postoperative infections and vials from which multiple patients were medicated (24); Bach et al. found similar results (30). In 1995, McHugh and Roper reported an incidence of 6.3% (16/254) of infection when propofol was administered from vials but did not find that delays in the administration of propofol were associated in any increased likelihood of bacterial contamination (25). Cole et al. recorded the incidence of contamination as high as 17.3% (26/150) in propofol found in stopcock dead space (27).

The distribution of instructions for aseptic measures for handling propofol has shown to reduce the rate of contaminated propofol. Lorenz et al. reported that after a specific protocol for handling propofol was introduced and adhered to, a reduction in extrinsic contamination was achieved when compared with only adhering to the manufacturer’s recommendations (8.8% versus 11.3%) (26). That protocol included additional aseptic precautions, such as refilling empty syringes for use on multiple patients by using a 3-way stopcock and replacing only the infusion line to the patient. Data from a study performed in a high-complexity hospital in Cali, Colombia, showed substantial microbial growth of

| Object†† and study, year (reference) | Country | Antimicrobial agents‡ | Hospital unit§ | Crude % contaminated propofol (no. contaminated/no. tested) |
|--------------------------------------|---------|----------------------|----------------|----------------------------------------------------------|
| Syringes                             |         |                      |                |                                                         |
| Farrington et al., 1994 (31)         | UK      | No                   | ICU            | 6.0 (3/50)                                               |
| Bach et al., 1997 (30)               | Germany | No                   | OR             | 4.8 (8/168)†‡ 5.1 (19/376)#                             |
| Webb et al., 1998 (23)               | Australia| ND                  | ICU            | 5.9 (18/302)                                             |
| Total                                |         |                      |                | 5.4 (48/969)**                                           |
| Vials                                |         |                      |                |                                                         |
| McHugh et al., 1995 (25)             | New Zealand | No | OR | 6.3 (16/254)                                             |
| Soong et al., 1999 (24)              | Australia | ND | OR | 3.0 (3/100)                                              |
| Zorrilla-Vaca et al., 2014 (32)      | Colombia | No | OR | 6.1 (12/198)                                             |
| Total                                |         |                      |                | 5.6 (31/552)**                                           |
| Infusion systems                     |         |                      |                |                                                         |
| Bach et al., 1997 (30)               | Germany | No                   | ICU            | 4.5 (10/224)†† 1.6 (5/318)#                             |
| Lorenz et al., 2002 (26)             | Austria | No                   | OR             | 11.3 (9/80),†† 8.8 (7/80)††                               |
| Total                                |         |                      |                | 4.4 (31/702)**                                           |
| IV stopcock dead spaces              |         |                      |                |                                                         |
| Cole et al., 2013 (27)               | United States | Yes | OR | 17.3 (26/150)                                            |

†ICU, intensive care unit; OR, operating room; ND, not described in publication; IV, intravenous.
††Clinical object from which residual propofol was taken to be cultured after clinical use.
‡Use of propofol formulations with antimicrobial additives.
§Hospital unit where the studies were conducted.
#Results of a first study period during February 1–October 31, 1992.
††Results of a second study-period from December 1, 1994, through March 31, 1995.
**Total crude percentage of contaminated propofol for each kind of object (syringes, vials, infusion systems).
†††Proportion of propofol contaminated, following the manufacturer’s handling recommendations.
‡‡‡Proportion of propofol contaminated, following a modified propofol handling protocol. (i.e., refilling empty syringes and renewing only the infusion line to the patient).
6.1% (12/198) in residual propofol vials used in ORs at a tertiary hospital in Cali (32).

By collating the incidences of contaminated propofol in containers or devices, the data suggest that it is more common to encounter contaminated previously used vials of propofol (5.6%, 31/552) than in used syringes (5.4%, 48/896) and infusion systems (4.4%, 31/702). Similarly, analyzed by hospital location, the percentage of contaminated propofol is greater in ORs (7.3%, 103/1,405) than in ICUs (4.0%, 36/894), correlating well with the expected prevalence of opened vials and syringes used for bolus injections of propofol for multiple patients in the OR compared with those in the ICUs.

**Risk for Infection Data Derived from Analytical Studies**

After we reviewed the initial microbiological studies, our interest increased in ascertaining potential links between the use of propofol infusions and the incidence of infections and sepsis after surgery. We analyzed 10 epidemiologic studies (Table 4; online Technical Appendix Table 1); of these, 4 assessed the associations with infection when practitioners followed manufacturers’ instructions for propofol handling, 5 assessed the association with infection when practitioners did not follow instructions, and 1 did not report on this issue.

Studies following manufacturers’ precautions stated such within the articles, but the degree of compliance of such precautions was not documented (online Technical Appendix Table 2). In 4 of 5 studies (80%) during which practitioners did not follow handling precautions, high infection risk was noted. In 4 studies in which precautions were followed, 2 (50%) scored above the significant risk threshold (online Technical Appendix Table 1). These findings underscore the controversy surrounding the utility of existing handling protocols and demonstrates the continued high potential of propofol as a causal factor of iatrogenic infection. Other authors have explain the susceptibility to infection because of the attenuation of the immunological activity caused by propofol infusions. More studies of specific handling protocols are required before a significant risk reduction is clearly observed. We developed an algorithmic approach that shows certain crucial measures to prevent future propofol-related outbreaks of infections (Figure 4); this approach was based on our analyses and summaries of the epidemiologic and clinical data selected.

**Proposed Propofol Formulations without Risk for Infection**

There are currently no propofol formulations without infection risk; however, several investigators have advocated the use of antimicrobial additives. As required by the FDA, the efficacy of such additives must retard microorganism growth to <10-fold at 24 hours after extrinsic contamination of propofol (1); many suggested antimicrobial agents have been rejected because of their poor efficacy, additional side effects, or higher costs (1). The fact that propofol is a lipid emulsion poses problems when additives are considered because admixture with other substances, especially charged species with differing

---

**Table 4. Summary of epidemiologic studies analyzing the association between infectious conditions and contaminated propofol anesthesia***

| Followed manufacturers’ precautions, study, year | Type of study | Preservative-free propofol† | Other agents compared with propofol | Type of infection | Hospital unit‡ | Association§ |
|------------------------------------------------|--------------|---------------------------|-----------------------------------|-----------------|----------------|-------------|
| Yes                                             | Retrospective cohort                     | Yes                        | Thiopentone                         | Sepsis          | OR             | No          |
| Seeberger et al., 1998                          | Case–control                               | ND                         | Sevoflurane                         | SSI             | OR             | Yes         |
| Shimizu et al., 2010                            | Case–control                               | Yes                        | ND                                 | Multiple¶       | ICU            | Yes         |
| Haddad et al., 2011                             | Case–control                               | Yes                        | ND                                 | BSI             | OR             | Yes         |
| Moehring et al., 2014                           | Case–control                               | Yes                        | Fentanyl                           | BSI             | ICU            | No          |
| No                                              | Case–control (2)                           | Yes                        | Sufentanil, alfentanil              | BSI, SSI        | OR             | Yes         |
| Bennett et al., 1995. (2)                       | Case–control                               | Yes                        | Sufentanil, fentanyl, midazolam, vecuronium | BSI, SSI, Fungemia, endophthalmitis | OR | Yes |
| Henry et al., 2001 (4)                          | Case–control                               | Yes                        | ND                                 | BSI             | OR             | Yes         |
| McNeil et al., 1999                            | Case–control                               | Yes                        | Sufentanil, fentanyl, midazolam, vecuronium | BSI, SSI, SIRS | OR | Yes |
| Sebert et al., 2002. Muller et al., 2010 (15)   | Case–control                               | ND                         | Fentanyl, midazolam                 | BSI             | SIRS           | No          |
| ND                                              | Case–control                               | ND                         | ND                                 | BSI             | ICU            | Yes         |
| Kontopoulou et al., 2012                        | Case–control                               | Yes                        | BSI, SIRS                           | OR              | Yes           |            |

*Complete data and full references are available in the online Technical Appendix (http://wwwnc.cdc.gov/EID/article/22/6/15-0376-Techapp1.pdf); OR, operating room; ICU, intensive care unit; BSI, bloodstream infection; SSI, Surgical site infection; ND, not described in publication; SIRS, systemic inflammatory response syndrome.

†Use of propofol without antimicrobial additives.
‡Hospital unit where the studies were conducted.
§Conclusion of the analytical study regarding the association between propofol exposure and infectious events.
¶Multiple infection types, including ventilator-associated pneumonia, urosepsis, BSI, catheter-related infections, and others.
partition coefficients, can interact with either the lipid phase or the emulsifying agents, resulting in emulsion destabilization. Older and newer advances on the use of additives are described in Table 5, which includes the scientific progress related to patients, clinical trials, original articles, and brief reports.

Propofol with EDTA
As an antimicrobial ion chelator, EDTA exerts its effect by removing divalent and trivalent metal cations, causing rupture of the microbial cell membrane by loss of control of osmotic pressure gradients. This combination is approved by the FDA; clinical trials demonstrated antimicrobial efficacy and safety in humans (18,36). For manufacturers, EDTA is the most broadly incorporated agent in combination with propofol formulations. Despite its widespread use, some controversy remains over its selection as the optimal additive (37). Moreover, in several developing countries, cost remains a considerable limiting factor for the use of EDTA-containing propofol formulations (A. Zorrilla-Vaca et al., unpub. data).

Fospropofol Disodium
A newly introduced agent, fospropofol disodium, is a water-soluble pro-drug of propofol that currently has a small evidence base for its use of 3 published clinical trials in the literature; in these studies, fospropofol was assessed for use in sedation for colonoscopies, bronchosopies, and coronary artery bypass graft surgery, and showed an acceptable safety profile (38). The advantage of this drug in reducing the risk for infectious events is that it does not have a lipophilic formulation that would support bacterial growth. Nonetheless, the drug has some disadvantages that could discourage its use, such as transient paresthesias and pruritis in the perineal and perianal regions (38).

Anesthetic Mixtures
Pain on injection is a common side effect of propofol. Anesthesiologists use a variety of strategies to reduce this, such as the addition of 1–2 mL of lidocaine to the propofol before injection. Lidocaine, like other amide local anesthetics, has bacteriostatic properties, which could theoretically reduce the chances of infection (29). It is, however, not currently known whether lidocaine has sufficient antimicrobial effect to make a clinical difference in infection rates.

Other Additives
Benzyl alcohol at concentrations of <2% has been used as a preservative agent in propofol formulations (39). Despite its bacteriostatic activity, benzyl alcohol used in propofol formulations is limited by its toxicity and instability in the combination. Other additives, such as phenylmercuric nitrate, phenylmercuric acetate, chlorobutanol, and phenol have been studied experimentally with propofol; however, all of these agents were rejected because of their potential toxicity. The sodium metabisulfite–containing formulation, created originally with the aim of reducing the pain of propofol injection, has been shown to possess preservative properties. Unfortunately, it has a labeled pH from 4.5 to 6.4, which is different from the FDA requirement of a pH of 6–8.5 for propofol (1). The nonlipid nanoemulsion and Emul-Siv filter are the most recent alternative propofol formulations (40). In recent studies, these formulations of propofol have attained a level of antimicrobial activity above that observed with propofol with EDTA (40). Costs are currently a limiting factor for their use, but these 2 options seem to provide some promise for the future if production costs decline.
Table 5. Description of advantages and disadvantages of each formulation of propofol related to contamination and iatrogenic infection*

| Propofol formulation | Settings | Advantages | Disadvantages | FDA approval |
|----------------------|----------|------------|---------------|--------------|
| Propofol with EDTA   | Antimicrobial activity | This mixture with propofol at 0.005% wt/vol concentration has demonstrated microbial growth to be retarded to ≥1 log CFUs (36), of nearly 20 microorganisms, including 7 Gram-positive bacteria, 10 Gram-negative bacteria, and 3 yeasts (18). Further, incidence of propofol-related infection declined from 39 to 9 infections per year in the USA, after the introduction of EDTA into clinical use in 1996 (18). | Decreases serum ionized calcium levels, although statistically significant, has apparently no clinical effect (time to complete recovery, p = 0.77 [37]). Also, EDTA is nephrotoxic at high doses (2–3 g/d). Concern that use of an antimicrobial may cause health personnel to relax on aseptic handling practices (1). | Yes |
| Fospropofol disodium | Nonlipophilic preparation | Because of water solubility, eliminates some of the known lipid emulsion-associated disadvantages of propofol, including the risk for infection (38). | Minor side effects (e.g., paresthesia, hypotension). The prolonged onset of action of fospropofol (=4–13 min, because of it must first undergo metabolism to propofol) compared with the prodrug propofol (>40 s). Allergies caused by the accumulation of a phosphate-ester component (38). | Yes† |
| Propofol and lidocaine | Bacteriostatic activity | Experimentally causes loss of viability of several strains (29). | Has no sufficient retarding effect. Possibilities of micelle formation exist. | No |
| Benzyl alcohol       | Antimicrobial activity | At low concentrations of ≥2%, has been used as a preservative agent. | Toxicity and presumed instability. | No |
| Sodium metabisulfite | Antimicrobial activity | Reduces the pain of propofol injection and has preservative properties. | Has a labeled pH of 4.5–6.4, which is different from the required pH for propofol (6–8.5) (1). | No |
| EmulSiv filter       | Filter | Use of the 0.45 μm-rated filter is purported to provide protection from accidental microbial contamination, particulate contamination and entrained air while maintaining the integrity of the emulsion (40). | High costs, not currently available. | No |
| Nonlipid propofol nanoemulsion | Nonlipophilic preparation | Replaces soybean lecithin with polyethylene glycol 660 hydroxystearate as propofol carrier (40). | High costs, not currently available. | No |

*FDA, US Food and Drug Administration.
†Approved for use by the FDA only for monitored anesthesia care; however, a decision from the US Drug Enforcement Agency could be scheduled (38).

Discussion

Contaminated propofol has been implicated in several episodes of iatrogenic infection in both the outpatient and inpatient settings, as well as in both surgical and nonsurgical patients (2,6,11,12,15). The risk for infection arises principally because the lipophilic nature of propofol supports microbial growth when the formulation becomes contaminated (2,6). In addition, the method of intravenous administration and the preservative-free preparations still used in many countries have been implicated in promoting infection with propofol use.

More than 2 decades have elapsed since the first outbreaks of contaminated propofol-related infection emerged in the United States (6), and incidents of contamination-related infections persist, despite the introduction of antimicrobial formulations. Contamination and infections associated with propofol have been most commonly reported in industrialized countries, but it is likely that this phenomenon is secondary to a lack of surveillance of propofol contamination in developing countries. Management of this risk for contamination and infection can be approached by continued medical education regarding patient safety. A lack of adherence to the manufacturers’ guidelines appears to have been a causative factor in most of the episodes reported worldwide. The adherence to strict aseptic handling protocols is mandatory and more education efforts (e.g., the One and Only Campaign, http://www.oneandonlycampaign.org/) are needed to generate awareness in the healthcare community of the importance of proper propofol practices.

In summary, healthcare-associated infections linked with contaminated propofol constitute a complex public health issue that requires a multifaceted approach. Further efforts in surveillance and research are required to reduce the potential harm from contaminated propofol. Healthcare practitioners must focus on standard hygienic measures and the increased use of approved antimicrobial propofol formulations. Following these simple tenets, the risk for in-use contamination would be lowered and the safety use profile for propofol would greatly improve.
Acknowledgments
We thank Alejandro Núñez for his help in retrieving articles.

Mr. Zorrilla-Vaca is a distinguished medical student at Universidad del Valle, Cali, Colombia, and trainee in anesthesiology at the Johns Hopkins University School of Medicine, Baltimore, MD, USA. His research interests are patient outcomes after general and regional anesthesia with particular focus on infectious and neurological complications.

References
1. Thompson KA, Goodale DB. The recent development of propofol (DIPRIVAN). Intensive Care Med. 2000;26:540–4. http://dx.doi.org/10.1007/PL00003783
2. Bennett SN, McNeil MM, Bland LA, Arduino MJ, Villarino ME, Perrotta DM, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med. 1995;333:147–54. http://dx.doi.org/10.1056/NEJM199507203330303
3. Weist K, Wilbrandt B, Herm T, Halle E, Melzer C, Rüden H. Severe cases of sepsis in an outpatient clinic caused by contaminated intravenous propofol (abstract). DGHM-Tagung Heidelberg. 2002.
4. Henry B, Plante-Jenkins C, Ostrowska K. An outbreak of Serratia marcescens associated with the anesthetic agent propofol. Am J Infect Control. 2001;29:312–5. http://dx.doi.org/10.1067/mic.2001.117043
5. Arduino MJ, Bland LA, McAllister SK, Aguero SM, Villarino ME, McNeil MM, et al. Microbial growth and endotoxin production in the intravenous anesthetic propofol. Infect Control Hosp Epidemiol. 1991;12:535–9. http://dx.doi.org/10.2307/30145228
6. Centers for Disease Control and Prevention. Posturgical infections associated with an extrinsically contaminated intravenous anesthetic agent—California, Illinois, Maine, and Michigan. 1990. MMWR Morb Mortal Wkly Rep. 1990;39:426–7.
7. King CA, Ogg M. Safe injection practices for administration of propofol. AORN J. 2012;95:365–72. http://dx.doi.org/10.1016/j.aorn.2011.06.009
8. Kuehner MJ, Webb RM, Jochimsen EM, Hancock GA, Arduino MJ, Hand S, et al. Staphylococcus aureus bloodstream infections among patients undergoing electroconvulsive therapy traced to breaks in infection control and possible extrinsic contamination by propofol. Anesth Analg. 1997;85:420–5.
9. Tallis GF, Ryan GM, Lambert SB, Bowden DS, McCarr R, Birch CJ, et al. Evidence of patient-to-patient transmission of hepatitis C virus through contaminated intravenous anaesthetic ampoules. J Viral Hepat. 2003;10:234–9. http://dx.doi.org/10.1046/j.1365-2893.2003.00424.x
10. Veber B, Gachot B, Bedos JP, Wolff M. Severe sepsis after intravenous injection of contaminated propofol. Anesthesiology. 1994;80:712–3. http://dx.doi.org/10.1097/00000542-199403000-00050
11. Massari M, Petrosillo N, Ippolito G, Solforsio L, Bonazzi L, Clementi M. Transmission of hepatitis C virus in a gynecological surgery setting. J Clin Microbiol. 2001;39:2860–3. http://dx.doi.org/10.1128/JCM.39.8.2860-2863.2001
12. Gutelius B, Perz JF, Parker MM, Hallack R, Stricoff R, Clement EJ, et al. Multiple clusters of hepatitis virus infections associated with anesthesia for outpatient endoscopy procedures. Gastroenterology. 2010;139:163–70. http://dx.doi.org/10.1053/j.gastro.2010.03.053
13. Acute hepatitis C virus infections attributed to unsafe injection practices at an endoscopy clinic—Nevada, 2007. MMWR Morb Mortal Wkly Rep. 2008;57:513–7.
14. Aparicio J, Sánchez-Paya J, Merino E, Martínez J, Ruiz F, Compañy L, et al. Outbreak of systemic candidiasis infection associated with propofol administration in an endoscopy unit (abstract) [in Spanish]. Endoscopy. 2010;42:A29. http://dx.doi.org/10.1055/s-2010-1268447
15. Muller AE, Huisman I, Roos PJ, Rietveld AP, Klein J, Harbers JB, et al. Outbreak of severe sepsis due to contaminated propofol: lessons to learn. J Hosp Infect. 2010;76:225–30. http://dx.doi.org/10.1016/j.jhin.2010.06.003
16. Chen SH, Kung CC, Feng ST. Endotoxemia due to propofol contamination in four consecutive patients. J Formos Med Assoc. 2014;113:328–9. http://dx.doi.org/10.1016/j.jfma.2013.08.012
17. Vonberg RP, Gastmeier P. Hospital acquired infections related to contaminated substances. J Hosp Infect. 2007;65:15–23. http://dx.doi.org/10.1016/j.jhin.2006.09.018
18. Jansson JR, Fukuda T, Ozaki M, Kimura S. Propofol EDTA and reduced incidence of infection. Anaesth Intensive Care. 2006;34:362–8.
19. Munoz-Price LS, Riley B, Banks S, Eber S, Arheart K, Lubarsky DA, et al. Frequency of interactions and hand disfections among anesthesiologists while providing anesthesia care in the operating room: induction versus maintenance. Infect Control Hosp Epidemiol. 2014;35:1056–9. http://dx.doi.org/10.1086/677154
20. Loftus RW, Koff MD, Burchman CC, Schwartzman JD, Thorun V, Read ME, et al. Transmission of pathogenic bacterial organisms in the anesthesia work area. Anesthesiology. 2008;109:399–407. http://dx.doi.org/10.1097/00000542-200812000-00025
21. Loftus RW, Patel HM, Huysman BC, Kispert DP, Koff MD, Gallagher JD, et al. Prevention of intravenous bacterial injection from health care provider hands: the importance of catheter design and handling. Anesth Analg. 2012;115:1109–19. http://dx.doi.org/10.1213/ANE.0b013e31826a1016
22. Maki DG, Klein B, McCormick R, Alvarado C, Stolz S, Ziliz M. Nosocomial Pseudomonas pickettii bacteremias traced to narcotic tampering. JAMA. 1991;265:981–6. http://dx.doi.org/10.1001/jama.1991.0346080051031
23. Webb SA, Roberts B, Breheny FX, Gollekde CL, Cameron PD, van Heerden PV. Contamination of propofol infusions in the intensive care unit: incidence and clinical significance. Aesaeuth Intensive Care. 1998;26:162–4.
24. Soong WA. Bacterial contamination of propofol in the operating theatre. Anaesth Intensive Care. 1999;27:493–6.
25. McHugh GJ, Roper GM. Propofol emulsion and bacterial contamination. Can J Anaesth. 2002;49:347–52. http://dx.doi.org/10.1007/s12112-002-2384-7
26. Lingnau W, et al. Routine handling of propofol prevents stopcock contamination. Anesth Analg. 2015;120:861–7. http://dx.doi.org/10.1213/ANE.0b013e31826a1016
27. Coll DC, Baslanti TO, Gravenstein NL, Gravenstein N. Leaving more than your fingerprint on the intravenous line: a prospective study on propofol anesthesia and implications of stopcock contamination. Anesth Analg. 2015;120:861–7. http://dx.doi.org/10.1213/ANE.0b013e31826a1016
28. Finkelstein A, Lokhandwala BS, Pandey NS. Particulate contamination of an intact gas amule. Anesthesiology. 1990;73:362–3. http://dx.doi.org/10.1097/00000542-199008000-00044
29. Aydin ON, Aydin N, Gultekin B, Ozgun S, Gurel A. Bacterial contamination of propofol: the effects of temperature and lidocaine. Eur J Anaesthesiol. 2002;19:455–8. http://dx.doi.org/10.1076/jane.0210777
30. Bach A, Motsch J, Schmidt H, Böttiger BW, Böhrer H, Martin H, et al. In-use contamination of propofol: A clinical study. Eur J Anaesthesiol. 1997;14:178–83. http://dx.doi.org/10.1097/00000542-20000542-00050
SYNOPSIS

31. Farrington M, McGinnes J, Matthews I, Park GR. Do infusions of midazolam and propofol pose an infection risk to critically ill patients? Br J Anaesth. 1994;72:415–7. http://dx.doi.org/10.1093/bja/72.4.415

32. Zorrilla-Vaca A, Escandon-Vargas K, Brand-Giraldo V, Leon T, Herrera M, Payan A. Bacterial contamination of propofol vials used in operating rooms of a third-level hospital. Am J Infect Control. 2015;44:e1-e3. http://dx.doi.org/10.1016/j.ajic.2015.08.009

33. Abdelmalak BB, Bashour CA, Yared JP. Skin infection and necrosis after subcutaneous infiltration of propofol in the intensive care unit. Can J Anaesth. 2008;55:471–3. http://dx.doi.org/10.1007/BF03016315

34. Yu HP, Tang GJ, Liaw WJ, Yien HW, Lee TY. Pseudomonas cepacia induced septic shock after propofol—a case report. Acta Anaesthesiol Sin. 2000;38:53–6.

35. Kim YD, Lee HK, Jwa YJ, Jung SK, Um TH, Cho CR, et al. A case of septic shock caused by Escherichia coli after intravenous injection of contaminated propofol [in Korean]. Infect Chemother. 2010;42:296–8. http://dx.doi.org/10.3947/ic.2010.42.5.296

36. Fukada T, Ozaki M. Microbial growth in propofol formulations with disodium edetate and the influence of venous access system dead space. Anaesthesia. 2007;62:575–80. http://dx.doi.org/10.1111/j.1365-2044.2007.05002.x

37. Cohen IT, Hannallah RS, Goodale DB. The clinical and biochemical effects of propofol infusion with and without EDTA for maintenance anesthesia in healthy children undergoing ambulatory surgery. Anesth Analg. 2001;93:106–11. http://dx.doi.org/10.1097/00000539-200107000-00023

38. Mahajan B, Kaushal S, Mahajan R. Fospropofol. J Pharmacol Pharmacother. 2012;3:293–6. http://dx.doi.org/10.4103/0976-500X.99457

39. Minogue SC, Sun DA. Bacteriostatic saline containing benzyl alcohol decreases the pain associated with the injection of propofol. Anesth Analg. 2005;100:683–6. http://dx.doi.org/10.1213/01.ANE.0000148617.98716.EB

40. Lourenço FR, Kikuhi IS, Yamamoto RN, Pinto TJ A. Extrinsic contamination of propofol non-lipid nanoemulsion [in Spanish]. Rev Bras Farm. 2012;93:504–9.

Address for correspondence: Andrés Zorrilla-Vaca, Faculty of Health, Universidad del Valle, Calle 4B # 36-00, Cali, 760026, Colombia; email: andres.zorrilla@correounivalle.edu.co

WORLD HEALTH DAYS

Visit the World Health Days section on our website for the latest articles and information on emerging infectious diseases in our global community.

http://wwwnc.cdc.gov/eid/page/world-health-days
Infectious Disease Risks Associated with Contaminated Propofol Anesthesia, 1989–2014

Technical Appendix

Epidemiologic Studies of Propofol-Related Infections

With the aim of comparing the risk of infections associated with propofol when following or not following manufacturers’ recommendations, we reviewed the analytical studies that have assessed the epidemiological relation between propofol exposure and healthcare-related infection. Technical Appendix Table 1 is a summary of all analytical studies found.

Data search provided 4 analytical studies following manufacturers’ recommendations. In 1998, Seeberger et al conducted a retrospective cohort and failed to document significant risk of infection following the manufacturers’ precautions (1). Recently, Moehring et al. obtained similar results (2). Contrary to these studies, Shimizu et al found a significant standardized infection risk following manufacturers’ precautions (standardized infection ratio 4.78, 95% CI 4.30–5.27, p = 0.02) (3). Also, Haddad et al found statistically significant risk of intensive care unit-acquired infections after propofol infusions following aseptic technique (adjusted odds ratio [aOR] 1.89, 95% CI 1.17–3.06, p = 0.009) and furthermore, they found significant risk of ICU-acquired sepsis as well (aOR 1.91, 95% CI 1.12–3.28, p = 0.02) (4). In regard with this evidence, we consider that there exists a lack of sufficiently effective measures for avoiding infections secondary to propofol use.

On the other hand, 5 analytical studies, in which personnel did not follow manufacturers’ guidelines, have been conducted. In 1995, Bennett et al. conducted a study in which 3 of 7 outbreaks were related to misuse of propofol (5). Henry et al conducted a case-control study with the aim of determining the risk factors associated with infection and
concluded that the infusion of propofol, without aseptic technique, was a significant risk factor (OR 22, 95% CI 2.1-550, p<0.05) (6). Also, McNeil et al obtained a significant infection risk (relative risk 8.8, p = 0.048) (7). Muller et al showed the strongest association, reporting infection in 7 out of 17 patients exposed to propofol and in none of the 18 unexposed patients (p = 0.003) (8). In particular, Sebert et al did not find significant risk of infection (9).

Another study by Kontopoulou et al found significant risk of infection, but the authors did not report if specific handling precautions were followed or not (10).

References
1. Seeberger MD, Staender S, Oertli D, Kindler CH, Marti W. Efficacy of specific aseptic precautions for preventing propofol-related infections: analysis by a quality-assurance programme using the explicit outcome method. J Hosp Infect. 1998;39:67–70. PubMed [http://dx.doi.org/10.1016/S0195-6701(98)90245-6]
2. Moehring RW, Lewis SS, Isaacs PJ, Schell WA, Thomann WR, Althaus MM, et al. Outbreak of bacteremia due to *Burkholderia contaminans* linked to intravenous fentanyl from an institutional compounding pharmacy. JAMA Intern Med. 2014;174:606–12. PubMed
3. Shimizu K, Hirose M, Mikami S, Takamura K, Goi T, Yamaguchi A, et al. Effect of anaesthesia maintained with sevoflurane and propofol on surgical site infection after elective open gastrointestinal surgery. J Hosp Infect. 2010;74:129–36. PubMed [http://dx.doi.org/10.1016/j.jhin.2009.10.011]
4. Haddad S, Tamim H, Memish ZA, Arabi Y. Association of preservative-free propofol use and outcome in critically ill patient. Am J Infect Control. 2011;39:141–7. PubMed [http://dx.doi.org/10.1016/j.ajic.2010.05.027]
5. Bennett SN, McNeil MM, Bland LA, Arduino MJ, Villarino ME, Perrotta DM, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol N Engl J Med. 1995;333:147–54. PubMed [http://dx.doi.org/10.1056/NEJM199507203330303]
6. Henry B, Plante-Jenkins C, Ostrowska K. An outbreak of *Serratia marcescens* associated with the anesthetic agent propofol. Am J Infect Control. 2001;29:312–5. PubMed [http://dx.doi.org/10.1067/mic.2001.117043]
7. McNeil MM, Lasker BA, Lott TJ, Jarvis WR. Postsurgical *Candida albicans* infections associated with an extrinsically contaminated. J Clin Microbiol. 1999;37:1398–403. PubMed

8. Muller AE, Huisman I, Roos PJ, Rietveld AP, Klein J, Harbers JB. Outbreak of severe sepsis due to contaminated propofol: lessons to learn. J Hosp Infect. 2010;76:225–30. PubMed http://dx.doi.org/10.1016/j.jhin.2010.06.003

9. Sebert ME, Manning ML, McGowan KL, Alpern ER, Bell LM. An outbreak of *Serratia marcescens* bacteremia after general anesthesia. Infect Control Hosp Epidemiol. 2002;23:733–9. PubMed http://dx.doi.org/10.1086/502003

10. Kontopoulou K, Tsepanis K, Vasiliagkou E, Katsanoulas K, Stoikou I, Antoniadou E, et al. Risk factors for *Burkholderia cepacia* complex bacteraemia among intensive care unit patients in a Greek general hospital [abstract]. Clin Microbiol Infect. 2012;18(S3):291. http://dx.doi.or/10.1111/j.1469-0691.2012.03802.x/abstract

11. King CA, Ogg M. Safe injection practices for administration of propofol. AORN J. 2012;95:365–72. PubMed http://dx.doi.org/10.1016/j.aorn.2011.06.009
### Technical Appendix Table 1. Summary of epidemiologic studies analyzing the association between infectious events and propofol*

| Followed manufacturers’ precautions | Study, year, (reference) | Type of study | Preservative-free propofol† | Others agents compared to propofol | Type of infection in the cases | Antimicrobial drug prophylaxis‡ | Hospital unit§ | Conclusions |
|------------------------------------|--------------------------|---------------|-----------------------------|-----------------------------------|-------------------------------|-----------------------------|----------------|----------------|
| Yes                                | Seeberger et al., 1998 (1) | Retrospective cohort | Yes                         | Thiopentone                       | Sepsis                        | Yes                         | Operating room | Infection rate in the propofol group: 0.2% (3/1,407). Infection rate in the thiopental group: 0.2% (10/5,026), p = NS. |
|                                    | Shimizu et al., 2010 (3)  | Cohort         | ND                          | Sevoflurane                       | SSI                           | Yes                        | Operating room | After matching, SSI rate in propofol group: 16.7% (14/84) and in sevoflurane group: 7.1% (6/84). SIR: 4.78 (95% CI 4.30–5.27), p = 0.02. |
|                                    | Haddad et al., 2011 (4)  | Nested cohort  | Yes                         | ND                               | Multiple¶                      | ND                         | ICU            | Risk for ICU-acquired infections, aOR: 1.89 (95% CI 1.17–3.06), p = 0.009. Risk for ICU-acquired sepsis, aOR: 1.91 (95% CI 1.12–3.28), p = 0.02. OR = 4.36 (95% CI 0.72–472.48), p = 0.19. |
|                                    | Moehring et al., 2014 (2) | Case-control   | ND                          | Fentanyl                         | BSI                           | Yes                        | ICU            | |
| No                                 | Bennett et al., 1995 (5) | Case-control and cohort | Yes                         | Sufentanil, alfentanil          | BSI, SSI                      | ND                         | Operating room | Hospital No. 2, RR: 8.8 Hospital No. 3, RR: 4.5 Hospital No. 6, RR: 20 p = ND |
|                                    | Henry et al., 2001. (6)  | Case-control   | Yes                         | ND                               | BSI, SSI                      | ND                         | Operating room | OR = 22 (95% CI 2.1–550), p<0.05. RR: 8.8, p = 0.048. |
|                                    | McNeil et al, 1999. (7)  | Cohort         | Yes                         | Sufentanil, fentanyl, midazolam, vecuronium | N D | Fusngemia, endophtha limitis | Yes                        | Operating room | |
|                                    | Sebert et al., 2002. (9) | Case-control   | ND                          | Fentanyl, midazolam             | BSI                           | Yes                        | Operating room | Exposed to propofol (7/17) versus unexposed (0/18), p = 0.003. |
|                                    | Muller et al, 2010. (8)  | Retrospective cohort | ND                         | ND                               | BSI, SIRS                      | Yes                        | Operating room | |
| ND                                 | Kontopoulou et al., 2012. (10) | Case-control | ND                          | ND                               | BSI                           | No                         | ICU            | OR = 5.23 (95% CI 2.2–8.46), p = 0.012. Infection rate in the propofol group: 0.2% (3/1,407). Infection rate in the thiopental group: 0.2% (10/5,026), p = NS. |

*ICU, intensive care unit; BSI, bloodstream infection; SSI, surgical site infection; SIRS, systemic inflammatory response syndrome; SIR, standardized infection ratio; OR, odds ratio; RR, risk ratio; aOR, adjusted odd ratio; 95% CI, 95% confidence interval; ND, not described in publication; NS, not significant.
†Use of propofol without antimicrobial additives.
‡Use of antimicrobial drug prophylaxis for the procedure.
§Hospital unit where the studies were conducted.
¶Ventilator-associated pneumonia, urosepsis, BSI, catheter-related infections, and others.
Technical Appendix Table 2. Manufacturers’ guidelines based on the instructions given by the US Centers for Disease Control and Prevention, US Food and Drug Administration, and the American Association of Anesthesiologists (11).

| Manufacturers’ guidelines                                                                 | Other recommendations by the CDC and FDA                                                                 |
|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| • Strict aseptic technique must always be used when handling sterile injectable medications   | • Vials of propofol and prefilled syringes are intended for single use (i.e., one patient).                |
| • Propofol should be inspected before use for particulate matter, discoloration, or evidence of separation of the emulsion. | • Infusion from prefilled syringes or vials must begin with 6 h of opening/filling the syringe.          |
| • Do not use if contaminated.                                                               | • Propofol that is infused directly from a large volume (e.g., 100 mL) vial is to be limited to one patient and must be infused within 12 h of opening the vial or spiking the stopper. |
| • Fill syringes or spike the vial immediately before administration to each patient.         | • Begin infusion immediately after drawing up or opening the medication vial.                          |
| • Disinfect the rubber stopper with 70% isopropyl alcohol.                                  |                                                                                                       |
| • Discard unused portions within 6 h of filling syringes or 12 h after spiking a large volume vial for infusion. |                                                                                                       |